keyword
MENU ▼
Read by QxMD icon Read
search

Yttrium-90

keyword
https://www.readbyqxmd.com/read/29786487/diffusion-weighted-mri-is-superior-to-pet-ct-in-predicting-survival-of-patients-undergoing-90-y-radioembolization-of-hepatic-metastases
#1
Alexandra Barabasch, Alexander Heinzel, Philipp Bruners, Nils A Kraemer, Christiane K Kuhl
Purpose To determine the relationship between diffusion-weighted (DW) liver MR images obtained 4-6 weeks after lobar yttrium 90 (90 Y) treatment and overall survival in comparison with PET/CT or established oncologic factors known to affect survival. Materials and Methods The institutional review board approved this prospective intraindividual comparative study in 36 consecutive patients (25 women) with liver-dominant metastases (20 colorectal, 14 breast, two other) (mean age, 60 years ± 10 [standard deviation]) who underwent fluorine 18 (18 F) fluorodeoxyglucose (FDG) PET/CT and DW MRI before and 4-6 weeks after 90 Y radioembolization...
May 21, 2018: Radiology
https://www.readbyqxmd.com/read/29754852/predictors-of-survival-after-yttrium-90-radioembolization-for-colorectal-cancer-liver-metastases
#2
Ashley A Weiner, Bin Gui, Neil B Newman, John L Nosher, Fady Yousseff, Shou-En Lu, Gretchen M Foltz, Darren Carpizo, Jonathan Lowenthal, Darryl A Zuckerman, Ben Benson, Jeffrey R Olsen, Salma K Jabbour, Parag J Parikh
PURPOSE: To identify clinical parameters that are prognostic for improved overall survival (OS) after yttrium-90 radioembolization (RE) in patients with liver metastases from colorectal cancer (CRC). MATERIALS AND METHODS: A total of 131 patients who underwent RE for liver metastases from CRC, treated at 2 academic centers, were reviewed. Twenty-one baseline pretreatment clinical factors were analyzed in relation to OS by the Kaplan-Meier method along with log-rank tests and univariate and multivariate Cox regression analyses...
May 10, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29753675/patient-radiation-exposure-in-transradial-versus-transfemoral-yttrium-90-radioembolization-a-retrospective-propensity-score-matched-analysis
#3
Joshua Loewenstern, Colton Welch, Safet Lekperic, Vivian Bishay, Mona Ranade, Rahul S Patel, Edward Kim, F Scott Nowakowski, Robert A Lookstein, Aaron M Fischman
PURPOSE: To compare differences in patient radiation exposure (PRE) during transarterial yttrium-90 (90 Y) radioembolization (TARE) between transradial access (TRA) and transfemoral access (TFA). MATERIALS AND METHODS: A total of 810 consecutive first-time TARE procedures in patients from 2013 to 2017 were retrospectively reviewed. A propensity score-matching (PSM) analysis matched TRA and TFA groups on the basis of patient age, sex, weight, height, cancer type, 90 Y microsphere type, and number of previous procedures from the same and opposite approaches...
May 9, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29737954/-90-y-radioembolization-for-hepatic-malignancy-in-patients-with-previous-biliary-intervention-multicenter-analysis-of-hepatobiliary-infections
#4
Kavi K Devulapalli, Nicholas Fidelman, Michael C Soulen, Matthew Miller, Matthew S Johnson, Eric Addo, Ghassan El-Haddad, Charles Nutting, James Morrison, Khashayar Farsad, R Peter Lokken, Ron C Gaba, Jacob Fleming, Daniel B Brown, Sharon W Kwan, Steven C Rose, Kevin A Pennycooke, David M Liu, Sarah B White, Ripal Gandhi, Ann A Lazar, Robert K Kerlan
Purpose To determine the frequency of hepatobiliary infections after transarterial radioembolization (TARE) with yttrium 90 (90 Y) in patients with liver malignancy and a history of biliary intervention. Materials and Methods For this retrospective study, records of all consecutive patients with liver malignancy and history of biliary intervention treated with TARE at 14 centers between 2005 and 2015 were reviewed. Data regarding liver function, 90 Y dosimetry, antibiotic prophylaxis, and bowel preparation prophylaxis were collected...
May 8, 2018: Radiology
https://www.readbyqxmd.com/read/29733658/bevacizumab-radioimmunotherapy-rit-with-accelerated-blood-clearance-using-the-avidin-chase
#5
Ryan Yudistiro, Hirofumi Hanaoka, Natsumi Katsumata, Aiko Yamaguchi, Yoshito Tsushima
The overexpression of vascular endothelial growth factor (VEGF) in varying types of solid tumor renders radioimmunotherapy (RIT) with the anti-VEGF antibody bevacizumab (BV) a promising treatment. However, the slow blood clearance of BV, which may increase the occurrence risk of hematotoxicity, hinders the application of BV-RIT. Using the avidin chase is a long-known blood clearance enhancement strategy for biotinylated-mAb. To enhance RIT efficacy by increasing the radioactivity dose, we evaluated the ability of avidin to accelerate the blood clearance of yttrium-90 (90 Y)-labeled biotinylated BV (90 Y-Bt-BV) in a xenograft mouse model of triple-negative breast cancer (TNBC)...
May 7, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29724520/long-term-toxicity-after-transarterial-radioembolization-with-yttrium-90-using-resin-microspheres-for-neuroendocrine-tumor-liver-metastases
#6
Yuki Tomozawa, Younes Jahangiri, Priya Pathak, Kenneth J Kolbeck, Ryan C Schenning, John A Kaufman, Khashayar Farsad
PURPOSE: To evaluate long-term effects of yttrium-90 (90 Y) transarterial radioembolization (TARE) for unresectable hepatic metastases of neuroendocrine tumors (NETs). MATERIALS AND METHODS: Retrospective analysis of 93 patients (47 women, 46 men; mean age 59 y) who underwent resin-based 90 Y TARE was performed. Variables associated with overall survival were analyzed using univariate and multivariate models. Changes in serologic values and imaging characteristics were assessed with long-term follow-up...
April 30, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29724518/response-and-overall-survival-for-yttrium-90-radioembolization-of-hepatic-sarcoma-a-multicenter-retrospective-study
#7
Matthew D Miller, Daniel Y Sze, Siddharth A Padia, Robert J Lewandowski, Riad Salem, Philani Mpofu, Paul M Haste, Matthew S Johnson
PURPOSE: To evaluate the effectiveness and safety of yttrium-90 transarterial radioembolization (TARE) for the treatment of primary and metastatic soft tissue sarcoma (STS) of the liver. MATERIALS AND METHODS: A retrospective review of 39 patients with primary (n = 2) and metastatic (n = 37) hepatic STS treated with TARE at 4 institutions was performed. Fourteen STS subtypes were included, with leiomyosarcoma being the most common (51%). TARE with glass (22 patients) or resin (17 patients) microspheres was performed, with single lobe (17 patients) or bilobar treatment (22 patients) based on disease burden...
April 30, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29705239/re-validation-of-response-to-yttrium-90-radioembolization-for-hepatocellular-carcinoma-with-portal-vein-invasion
#8
Carlo Sposito, Carlo Spreafico, Vincenzo Mazzaferro
No abstract text is available yet for this article.
April 26, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29683787/selective-internal-radiation-therapy-sirt-as-treatment-for-hepatic-metastases-of-uveal-melanoma-a-finnish-nation-wide-retrospective-experience
#9
Sanni Tulokas, Hanna Mäenpää, Erno Peltola, Tero Kivelä, Pia Vihinen, Aku Virta, Siru Mäkelä, Raija Kallio, Micaela Hernberg
BACKGROUND: In Finland, selective internal radiation therapy (SIRT) is at present the preferred first-line loco-regional therapy for uveal melanoma patients with hepatic metastases not suitable for surgery. We retrospectively evaluate the outcome and safety of SIRT in this group of patients. MATERIAL AND METHODS: Yttrium-90 microspheres were delivered via the hepatic artery into the circulation of metastases from uveal melanoma in 18 patients with a predicted life expectancy of more than three months in three Finnish tertiary referral centers between November 2010 and December 2015...
April 23, 2018: Acta Oncologica
https://www.readbyqxmd.com/read/29663029/yttrium-90-ibritumomab-tiuxetan-zevalin-followed-by-beam-z-beam-conditioning-regimen-and-autologous-stem-cell-transplantation-asct-in-relapsed-or-refractory-high-risk-b-cell-non-hodgkin-lymphoma-nhl-a-single-institution-italian-experience
#10
Chiara Ciochetto, Barbara Botto, Roberto Passera, Marilena Bellò, Giulia Benevolo, Carola Boccomini, Alessia Castellino, Annalisa Chiappella, Roberto Freilone, Maura Nicolosi, Lorella Orsucci, Clara Pecoraro, Patrizia Pregno, Gianni Bisi, Umberto Vitolo
Chemo-refractory NHL has a very poor outcome; the addiction of RIT to salvage regiment pre ASCT had recently demonstrated promising results.We performed a retrospective sequential study to determine the feasibility of standard Zevalin with BEAM in high-risk relapse/refractory NHL. A matched cohort analysis with a group treated with standard BEAM without Zevalin was performed as secondary endpoint. Between October 2006 and January 2013, 37 NHL patients at high risk for progression or early (< 1 year) or multiple relapses were treated with Z-BEAM and ASCT after R-DHAP or R-ICE as salvage therapy...
April 16, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29651580/hepatotoxic-dose-thresholds-by-positron-emission-tomography-after-yttrium-90-radioembolization-of-liver-tumors-a-prospective-single-arm-observational-study
#11
Keith T Chan, Adam M Alessio, Guy E Johnson, Sandeep Vaidya, Sharon W Kwan, Wayne Monsky, Ann E Wilson, David H Lewis, Siddharth A Padia
PURPOSE: To define a threshold radiation dose to non-tumoral liver from 90 Y radioembolization that results in hepatic toxicity using pair-production PET. MATERIALS AND METHODS: This prospective single-arm study enrolled 35 patients undergoing radioembolization. A total of 34 patients (27 with HCC and 7 with liver metastases) were included in the final analysis. Of 27 patients with underlying cirrhosis, 22 and 5 patients were Child-Pugh A and B, respectively. Glass and resin microspheres were used in 32 (94%) and 2 (6%) patients, respectively...
April 12, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29616365/multi-institutional-quantitative-phantom-study-of-yttrium-90-pet-in-pet-mri-the-mr-quest-study
#12
Nichole M Maughan, Mootaz Eldib, David Faul, Maurizio Conti, Mattijs Elschot, Karin Knešaurek, Francesca Leek, David Townsend, Frank P DiFilippo, Kimberly Jackson, Stephan G Nekolla, Mathias Lukas, Michael Tapner, Parag J Parikh, Richard Laforest
BACKGROUND: Yttrium-90 (90 Y) radioembolization involves the intra-arterial delivery of radioactive microspheres to treat hepatic malignancies. Though this therapy involves careful pre-treatment planning and imaging, little is known about the precise location of the microspheres once they are administered. Recently, there has been growing interest post-radioembolization imaging using positron-emission tomography (PET) for quantitative dosimetry and identifying lesions that may benefit from additional salvage therapy...
April 4, 2018: EJNMMI Physics
https://www.readbyqxmd.com/read/29578364/treatment-of-hepatocellular-carcinoma-a-cost-analysis-of-yttrium-90-transarterial-radioembolization-versus-sorafenib
#13
Maria Grazia Lucà, Roberto Nani, Melanie Schranz, Massimo De Giorgio, Claudia Iegri, Roberto Agazzi, Francesco Sala, Giorgio Virotta, Donatella Sarti, Grazia Conte, Domenico Pinelli, Carlo Nicora, Michele Colledan, Sandro Sironi, Stefano Fagiuoli
AIM: The aim was to evaluate cost-effectiveness of yttrium-90 transarterial radioembolization (TARE) in comparison to sorafenib treatment. PATIENTS & METHODS: A single-center, retrospective, observational study was performed, 166 patients with intermediate-/advanced-stage hepatocellular carcinoma were treated with sorafenib and 19 with TARE. The patients out of the sorafenib group matching the inclusion criteria for TARE, were reassigned to a subgroup SOR3...
April 2018: Future Oncology
https://www.readbyqxmd.com/read/29559288/prospective-trial-using-internal-pair-production-positron-emission-tomography-to-establish-the-yttrium-90-radioembolization-dose-required-for-response-of-hepatocellular-carcinoma
#14
Keith T Chan, Adam M Alessio, Guy E Johnson, Sandeep Vaidya, Sharon W Kwan, Wayne Monsky, Ann E Wilson, David H Lewis, Siddharth A Padia
PURPOSE: To prospectively assess the threshold dose for objective response of hepatocellular carcinoma (HCC), using90 Y internal pair-production positron emission tomography (PET) to quantify the radiation dose delivered to hepatic tumors after radioembolization. METHODS AND MATERIALS: A prospective study was performed under institutional review board approval from 2012 to 2014. Thirty-five patients with primary and secondary liver tumors undergoing90 Y treatment were recruited...
February 9, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29523614/selective-internal-radiation-therapy-sirt-with-yttrium-90-microspheres-for-unresectable-intrahepatic-cholangiocarcinoma
#15
Vindya Abeysinghe, Siva Sundararajan, Luc Delriviere, Jonathan Tibballs
Unresectableintrahepaticcholangiocarcinoma has a very poor prognosis despite various treatment options. The case presented describes the diagnostic challenges of a young pregnant woman with unresectable cholangiocarcinoma. The current treatment options for cholangiocarcinoma have limited evidence and high recurrence rate. Given the young age of this patient, selective internal radiotherapy was trialled with traditional chemotherapy with a clinically significant result. This case highlights the delays when diagnosing cholangiocarcinoma in younger patients and the possibility of selective internal radiation therapy in combination with chemotherapy as a potential first-line treatment for a complete response in unresectable disease...
March 9, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29520178/imaging-evaluation-following-90-y-radioembolization-of-liver-tumors-what-radiologists-should-know
#16
REVIEW
Ijin Joo, Hyo-Cheol Kim, Gyoung Min Kim, Jin Chul Paeng
Radioembolization using beta-emitting yttrium-90 microspheres is being increasingly used for the treatment of primary and metastatic liver cancers. It is a form of intra-arterial brachytherapy which delivers intense radiation to liver tumors with little embolic effect; this mode of action results in unique post-treatment imaging findings. It is important to understand these imaging findings to avoid misinterpretation of tumor response and to determine further management of the disease. Herein, we discuss the current concepts for assessing tumor response, common post-treatment imaging features, and associated complications following radioembolization...
March 2018: Korean Journal of Radiology: Official Journal of the Korean Radiological Society
https://www.readbyqxmd.com/read/29516130/radioembolisation-in-patients-with-hepatocellular-carcinoma-that-have-previously-received-liver-directed-therapies
#17
Bruno Sangro, Carlo Ludovico Maini, Giuseppe Maria Ettorre, Roberto Cianni, Rita Golfieri, Daniele Gasparini, Samer Ezziddin, Philipp M Paprottka, Francesco Fiore, Mark Van Buskirk, Jose Ignacio Bilbao, Rita Salvatori, Emanuela Giampalma, Onelio Geatti, Kai Wilhelm, Ralf Thorsten Hoffmann, Francesco Izzo, Mercedes Iñarrairaegui, Carlo Urigo, Alberta Cappelli, Alessandro Vit, Hojjat Ahmadzadehfar, Tobias Franz Jakobs, Rosa Sciuto, Giuseppe Pizzi, Secondo Lastoria
PURPOSE: Radioembolisation is part of the multimodal treatment of hepatocellular carcinoma (HCC) at specialist liver centres. This study analysed the impact of prior treatment on tolerability and survival following radioembolisation. METHODS: This was a retrospective analysis of 325 consecutive patients with a confirmed diagnosis of HCC, who received radioembolisation with yttrium-90 resin microspheres at eight European centres between September 2003 and December 2009...
March 7, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29498924/sirvenib-selective-internal-radiation-therapy-versus-sorafenib-in-asia-pacific-patients-with-hepatocellular-carcinoma
#18
Pierce K H Chow, Mihir Gandhi, Say-Beng Tan, Maung Win Khin, Ariunaa Khasbazar, Janus Ong, Su Pin Choo, Peng Chung Cheow, Chanisa Chotipanich, Kieron Lim, Laurentius A Lesmana, Tjakra W Manuaba, Boon Koon Yoong, Aloysius Raj, Chiong Soon Law, Ian H Y Cua, Rolley R Lobo, Catherine S C Teh, Yun Hwan Kim, Yun Won Jong, Ho-Seong Han, Si-Hyun Bae, Hyun-Ki Yoon, Rheun-Chuan Lee, Chien-Fu Hung, Cheng-Yuan Peng, Po-Chin Liang, Adam Bartlett, Kenneth Y Y Kok, Choon-Hua Thng, Albert Su-Chong Low, Anthony S W Goh, Kiang Hiong Tay, Richard H G Lo, Brian K P Goh, David C E Ng, Ganesh Lekurwale, Wei Ming Liew, Val Gebski, Kenneth S W Mak, Khee Chee Soo
Purpose Selective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the safety and efficacy of RE and sorafenib in patients with locally advanced HCC. Patients and Methods SIRveNIB (selective internal radiation therapy v sorafenib), an open-label, investigator-initiated, phase III trial, compared yttrium-90 (90 Y) resin microspheres RE with sorafenib 800 mg/d in patients with locally advanced HCC in a two-tailed study designed for superiority/detriment...
March 2, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29496075/yttrium-90-radioembolization-for-unresectable-metastatic-neuroendocrine-liver-tumor-a-systematic-review
#19
REVIEW
Zhongzhi Jia, Weiping Wang
OBJECTIVE: To evaluate the value of yttrium-90 (90 Y) microspheres in the management of unresectable liver metastases secondary to neuroendocrine tumors (NETs). MATERIALS AND METHODS: PubMed, EMBASE, the Cochrane Database of Systematic Reviews, and the "gray" literature (Google Scholar) were searched for all studies related to 90 Y therapy for unresectable liver metastases of NETs. RESULTS: A total of 11 studies and 7 abstracts involving 870 patients were included in the final analysis...
March 2018: European Journal of Radiology
https://www.readbyqxmd.com/read/29476021/updated-results-of-rituximab-pre-and-post-beam-with-or-without-90-yttrium-ibritumomab-tiuxetan-during-autologous-transplant-for-diffuse-large-b-cell-lymphoma
#20
Jad Chahoud, Dawen Sui, William D Erwin, Alison M Gulbis, Martin Korbling, Mingzhi Zhang, Sairah Ahmed, Gheath Alatrash, Paolo Anderlini, Stefan O Ciurea, Betul Oran, Luis E Fayad, Roland L Bassett, Elias J Jabbour, L Jeffrey Medeiros, Homer A Macapinlac, Ken H Young, Issa F Khouri
Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan (90 YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (ASCT). Experimental design: Patients were enrolled on three consecutive phase II clinical trials. Patients received two doses of rituximab (375 and 1,000 mg/m2 ) during mobilization of stem cells, followed by 1,000 mg/m2 on days +1 and +8 after ASCT with R-BEAM or 90 YIT-R-BEAM (90 YIT dose of 0...
February 23, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
33486
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"